Reality Check on Hypertension
Market access for hypertension treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: About 44% of the lives under commercial formularies are unrestricted
- Class Trends: With a wide variety of generic drugs available, brand name hypertension drugs are rarely prescribed to patients, and costs for both payers and members remain low
- Key Findings: Pharmacy benefit coverage is extensive for most products, and formulary status is favorable by default
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.